Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, obtained a $200 million term loan facility from Hercules Capital.
SCYNEXIS secured a $60 million term loan facility with Hercules Capital and Silicon Valley Bank. The capital strengthens SCYNEXIS’ balance sheet ahead of the anticipated commercial launch of Brexafemme, an oral antifungal product for the treatment of vaginal yeast infections.
Hercules Capital entered into a $100 million debt financing agreement with G1 Therapeutics, a clinical-stage oncology company. G1 plans to use the proceeds to fund commercialization and further development of trilaciclib.
K2 HealthVentures will provide a debt financing facility for up to $50 million to VBI Vaccines, a commercial-stage biopharmaceutical company developing infectious disease and immuno-oncology vaccines.
Viveve Medical entered into a $30 million senior credit facility with affiliates of CRG to retire its existing credit facility and provide additional capital for the company.